386 件の文書 found
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 GADS-1 gadolinium isotopic CRM for laboratory use. SDS Section 3 lists nitric acid 2.0% (CAS 7697-37-2) and gadolinium oxide 0.1% (CAS 12064-62-9). 改訂版 2019年8月26日, version 1.0. 情報源: National Research Council Canada. Licensed under the 開く Government Licence – Canada.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 GADS-1, matériau de référence certifié isotopique du gadolinium pour utilisation en laboratoire. La section 3 de la FDS indique 2,0 % d'acide nitrique (CAS 7697-37-2) et 0,1 % de trioxyde de digadolinium (CAS 12064-62-9). Révision du 26 août 2019, version 1,0. 情報源 : Conseil national de recherches Canada. Licence du gouvernement ouvert – Canada.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Radioactive monazite reference material containing cerium, lanthanum, praseodymium, neodymium and optional yttrium phosphates, with thorium and uranium phosphates and quartz listed in Section 3. Original 17-page SDS revised 2020年6月24日. U.S. Department of Energy government information; republished with acknowledgement under DOE web policy: https://www.energy.gov/web-policies
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Earlier official revision of the radioactive monazite reference-material SDS. Section 3 lists cerium, lanthanum, praseodymium, neodymium and optional yttrium phosphates, plus thorium and uranium phosphates and quartz. Created 2011年7月29日 and revised 2014年10月8日. U.S. Department of Energy government information; republished with acknowledgement under DOE web policy: https://www.energy.gov/web-policies
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Mineral sands concentrate used as raw material for rare-earth compounds. Section 3 is a multi-mineral mixture; CAS numbers and composition are retained only as stated by the original SDS. 改訂版 2022年10月4日. 情報源: RZ Resources Ltd. Publication authorization confirmed by the RESDS site owner on 2026年9月14日.
Original Bracco safety data sheet for MultiHance (CAN). 原本PDF retained without modification. 情報源 collected on 2026-09-13.
Original Lorad safety data sheet for Praseodymium-doped gadolinium oxysulfide. 原本PDF retained without modification. 情報源 collected on 2026-09-13.
Original Bracco safety data sheet for ProHance - Gadoteridol injection. CAS entries are substances/components identified in the original SDS: 7732-18-5; 120066-54-8; 77-86-1. 原本PDF retained without modification. 情報源 collected on 2026-09-13.
Original Bracco safety data sheet for ProHance - Gadoteridol injection. CAS entries are substances/components identified in the original SDS: 120066-54-8; 121915-83-1; 77-86-1. 原本PDF retained without modification. 情報源 collected on 2026-09-13.
Original Saint-Gobain / Luxium Solutions safety data sheet for SGGG (Gallium and Gadolinium Substituted Garnet). 原本PDF retained without modification. 情報源 collected on 2026-09-13.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original Strem SDS for Tetrakis(2,2,6,6-tetramethyl-3,5-heptanedionato)cerium(IV), min. 97% (99.9%-Ce) (REO). Product number 58-5000; revision 07/18/2021. Publication authorized by the user on 2026-09-14.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original Strem SDS for Tetrakis[1-(methoxy)-2-methyl-2-propanolato] cerium, [Ce(mmp)4], 98%. Product number 58-5500; revision 18.07.2021. Publication authorized by the user on 2026-09-14.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)europium (III). Product number: ALFAA87898. 原本改訂日: 27-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gadolinium (III). Product number: ALFAA14486. 原本改訂日: 22-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.
Original Alfa-Aesar safety data sheet for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gadolinium (III). 原本PDF retained without modification. 情報源 collected on 2026-09-13.
Original Strem safety data sheet for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gadolinium (III), 99% (99.9%-Gd) (REO) [Gd(TMHD)3]. 原本PDF retained without modification. 情報源 collected on 2026-09-13.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original Strem SDS for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gadolinium (III), 99% (99.9%-Gd) (REO). Product number 64-5000; revision 07/18/2021. Publication authorized by the user on 2026-09-14.
Original Ereztech safety data sheet for Tris(2,2,6,6-tetramethyl-3,5-heptanedionato)gadolinium(III). Archive note: 旧版字体编码影响复制/检索；页面已抽样确认可显示；原PDF未改动。 原本PDF retained without modification. 情報源 collected on 2026-09-13.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(4,4,4-trifluoro-1-(2-thienyl)-1,3-butanediono)europium (III). Product number: ALFAA43345. 原本改訂日: 23-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionato)europium (III). Product number: ALFAA33541. 原本改訂日: 24-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(dibenzoylmethane)mono(phenanthroline)europium (III). Product number: ALFAA44175. 原本改訂日: 31-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original Strem SDS for Tris(i-propylcyclopentadienyl)gadolinium(III), 98% (99.9%-Gd) (REO). Product number 64-6000; revision 07/14/2021. Publication authorized by the user on 2026-09-14.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original Strem SDS for Tris(N,N'-di-i-propylformamidinato)gadolinium(III), Gd-FMD. Product number 64-3575; revision 07/18/2021. Publication authorized by the user on 2026-09-14.
RESDSが収集し、発行元の原本PDFをそのまま保持しています。 Original manufacturer safety data sheet for Tris(trifluoromethylhydroxymethylene-d-camphorato)europium (III). Product number: ALFAA88481. 原本改訂日: 24-Jul-2026. 公開日 under the file-level authorization confirmed by the user for the frozen 1,125-file manifest.